| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213
Address all correspondence and requests for reprints to: Andrew F. Stewart, M.D., Division of Endocrinology, BST E-1140, University of Pittsburgh School of Medicine, 3550 Terrace Street, Pittsburgh, Pennsylvania 15213. E-mail: stewart{at}msx.dept-med.pitt.edu.
Islet transplantation for diabetes is limited by the availability of human islet donors. Hepatocyte growth factor (HGF) is a potent ß-cell mitogen and survival factor and improves islet transplant outcomes in a murine model. However, the murine model employs renal subcapsular transplant and immunodeficient mice, features not representative of human islet transplantation protocols. Therefore, we have developed a more rigorous, marginal-mass rat islet transplant model that more closely resembles human islet transplantation protocols: islet donors are allogeneic Lewis islets; recipients are normal Sprague Dawley rats; islets are delivered intraportally; and immunosuppression is accomplished using the same immunosuppressants employed by the Edmonton group. We demonstrate that 1) surprisingly, the Edmonton immunosuppression regimen induces marked insulin resistance and ß-cell toxicity in rats, 2) adenovirus does not adversely affect islet transplant outcomes, 3) the Edmonton immunosuppressants may delay or block rejection of adenovirally transduced islets, and more importantly, 4) pretransplant islet adenoviral gene therapy with HGF markedly improves islet transplant outcomes, 5) this enhanced function persists for months, and 6) HGF enhances islet function and survival even in the setting of immunosuppressant-induced insulin resistance and ß-cell toxicity. This approach may enhance islet transplantation outcomes in humans.
This article has been cited by other articles:
 |
|
 |
|
  N. Fiaschi-Taesch, T. A. Bigatel, B. Sicari, K. K. Takane, F. Salim, S. Velazquez-Garcia, G. Harb, K. Selk, I. Cozar-Castellano, and A. F. Stewart Survey of the Human Pancreatic {beta}-Cell G1/S Proteome Reveals a Potential Therapeutic Role for Cdk-6 and Cyclin D1 in Enhancing Human {beta}-Cell Replication and Function In Vivo Diabetes, April 1, 2009; 58(4): 882 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Kim, J.-W. Kim, C. Sun, S. T. Oh, K. H. Yoon, and S. K. Lee Induction of Efficient Differentiation and Survival of Porcine Neonatal Pancreatic Cell Clusters Using an EBV-based Plasmid Expressing HGF J. Biochem., April 1, 2008; 143(4): 497 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Rivas-Carrillo, A. Soto-Gutierrez, N. Navarro-Alvarez, H. Noguchi, T. Okitsu, Y. Chen, T. Yuasa, K. Tanaka, M. Narushima, A. Miki, et al. Cell-Permeable Pentapeptide V5 Inhibits Apoptosis and Enhances Insulin Secretion, Allowing Experimental Single-Donor Islet Transplantation in Mice Diabetes, May 1, 2007; 56(5): 1259 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Santangelo, P. Matarrese, R. Masella, M. C. Di Carlo, A. Di Lillo, B. Scazzocchio, E. Vecci, W. Malorni, R. Perfetti, and E. Anastasi Hepatocyte growth factor protects rat RINm5F cell line against free fatty acid-induced apoptosis by counteracting oxidative stress J. Mol. Endocrinol., January 1, 2007; 38(1): 147 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.M. J. Shapiro, C. Ricordi, B. J. Hering, H. Auchincloss, R. Lindblad, R. P. Robertson, A. Secchi, M. D. Brendel, T. Berney, D. C. Brennan, et al. International Trial of the Edmonton Protocol for Islet Transplantation. N. Engl. J. Med., September 28, 2006; 355(13): 1318 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Zhang, D. Su, S. Qu, T. Tse, R. Bottino, A.N. Balamurugan, J. Xu, J. S. Bromberg, and H. H. Dong Sirolimus Is Associated With Reduced Islet Engraftment and Impaired {beta}-Cell Function Diabetes, September 1, 2006; 55(9): 2429 - 2436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Narang and R. I. Mahato Biological and biomaterial approaches for improved islet transplantation. Pharmacol. Rev., June 1, 2006; 58(2): 194 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Rickels, A. Naji, and K. L. Teff Insulin Sensitivity, Glucose Effectiveness, and Free Fatty Acid Dynamics after Human Islet Transplantation for Type 1 Diabetes J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2138 - 2144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Emamaullee, R. V. Rajotte, P. Liston, R. G. Korneluk, J. R.T. Lakey, A.M. J. Shapiro, and J. F. Elliott XIAP Overexpression in Human Islets Prevents Early Posttransplant Apoptosis and Reduces the Islet Mass Needed to Treat Diabetes Diabetes, September 1, 2005; 54(9): 2541 - 2548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Mysore, T. A. Shinkel, J. Collins, E. J. Salvaris, N. Fisicaro, L. J. Murray-Segal, L. E.A. Johnson, D. A. Lepore, S. N. Walters, R. Stokes, et al. Overexpression of Glutathione Peroxidase With Two Isoforms of Superoxide Dismutase Protects Mouse Islets From Oxidative Injury and Improves Islet Graft Function Diabetes, July 1, 2005; 54(7): 2109 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hui, N. Khoury, X. Zhao, L. Balkir, E. D'Amico, A. Bullotta, E. D. Nguyen, A. Gambotto, and R. Perfetti Adenovirus-Mediated XIAP Gene Transfer Reverses the Negative Effects of Immunosuppressive Drugs on Insulin Secretion and Cell Viability of Isolated Human Islets Diabetes, February 1, 2005; 54(2): 424 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Harlan Gene-Altered Islets for Transplant: Giant Leap or Small Step? Endocrinology, February 1, 2004; 145(2): 463 - 466. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
